ASCO 2022 | ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
Sattva Neelapu
• 5 Jun 2022
Sattva Neelapu, MD, MD Anderson Cancer Center, Houston, TX, provides an overview of the results of ZUMA-12 (NCT03761056), a Phase II trial evaluating axicabtagene ciloleucel (axi-cel) as first-line therapy in high-risk large B-cell lymphoma. The primary endpoint in efficacy-evaluable patients was met, with a 78% complete response rate and an 89% objective response rate. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
